Oleg graduated from the Faculty of Biology with a major in Biophysics and the Faculty of Computational Mathematics and Cybernetics with a degree in Applied Mathematics of the Lomonosov Moscow State University in 1992. He completed his Ph.D. in Biophysics in 1995. From 1994 to 2000 he worked as a visiting scientist at the Amsterdam Free University (Amsterdam, Netherlands) and the Thomas Jefferson University (Philadelphia, USA). Since 1996 he worked at the Belozersky Institute of Physical and Chemical Biology and Lomonosov Moscow State University. In 2009, he held the position of Scientific Director, and since 2013 he is the CEO of the company. Oleg is a co-founder of InSysBio.
Oleg has extensive modeling experience in various fields of biology and biotechnology. At InSysBio he is engaged in systems biological modeling of signal and metabolic pathways; systems pharmacological modeling in such areas as inflammatory processes and immunology, oncology, neurodegenerative diseases, diabetes, hepatitis C.
Sergey graduated from the Faculty of Biology of the Lomonosov Moscow State University in 1980 with a major in Biochemistry and the Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry in 1984 as a postgraduate in enzyme kinetics. From 1984 to 1997 he worked at the Institute of Bioorganic Chemistry studying cellular processes in inflammation. Sergey joined InSysBio in 2002, and is engaged in systems biology modeling of signaling pathways and systems pharmacological modeling in such areas as inflammatory processes and immunology, diabetes, hepatitis C, body weight regulation. Sergey is a co-founder of InSysBio.
Evgeny graduated from Physical department of the Lomonosov Moscow State University in 2004 with a Master of Science in Biochemical physics and completed his PhD in Biophysics in 2008. Evgeny joined InSysBio in 2004. Since then he has extensive modeling experience being engaged into such projects as modeling of energy metabolism in mitochondria; PBPK modeling of proteins and nanoparticles; population PK/PD modeling of biotherapeutics to support decisions in clinical and preclinical studies; modeling of anti-inflammatory therapy against COPD, Rheumatoid arthritis and coronary arterial disease; QSP modeling for the analysis of clinical data on FAAH inhibitor for chronic pain treatment; development and maintaining of software tools for modeling and data analysis: DBSolve, Circulator, HetaSimulator, LikelihoodProfiler, etc. Evgeny is a co-founder of InSysBio.
Now Evgeny is mainly focused on such areas as the development of infrastructure for QSP modeling, identifiability and sensitivity analysis, methodology and optimal modeling workflow in QSP projects.
Oleg graduated from the Faculty of Bioengineering and Bioinformatics of the Lomonosov Moscow State University in 2010. He started working at InSysBio in 2008 as an intern. Oleg was involved as a modeler and project leader in multiple QSP and mechanistic modeling projects in various therapeutic areas including immunology, inflammation, virology, neurodegeneration, metabolic diseases, oncology, and immuno-oncology. Since 2017 and until the end of 2019 he has been working as Head of Business Development of InSysBio. Oleg currently holds the position of Scientific & Marketing Director in Oncology & Immuno-Oncology. Oleg is a co-founder of InSysBio. He is engaged in QSP modeling of solid and liquid tumors treatment with mAbs, bispecific antibodies, engineered T-cell therapies, cytokines, and small molecules. Oleg is one of the authors of the Immune Response Template (IRT) platform and was the head of the IRT research project. He is also an academic supervisor of a number of undergraduate and graduate theses at such universities as the Pirogov Russian National Research Medical University and the Moscow State University.
Tatiana graduated from the Faculty of Physics of the Lomonosov Moscow State University with a major in Biophysics. At MSU she also completed her Ph.D. in theoretical modeling of photosynthetic processes and taught Fundamentals of Quantum Chemistry. She has worked at InSysBio since 2009. She was engaged in projects on modeling of bacterial metabolism; systems pharmacological models in such therapeutic areas as asthma, hepatitis C, Alzheimer's disease, renal hydrodynamics. Tatiana develops population models, including those related to oncology, and also participates in the development of approaches to big data analysis. Tatiana is the developer of Alzheimer’s Disease Platform. Tatiana is a co-founder of InSysBio.
Tatiana is the author of publications on systems pharmacological and population modeling. She was the leader of the team that took the 2nd place out of 33 teams at the DREAM challenge 2014 (Acute myeloid leukemia outcome prediction challenge).